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1. Introduction
  Tuberculosis (TB) is one of the most important causes of 
disease and death worldwide, mainly in Africa and Asia. In 
the year 2006, 9 million new cases of TB were presented, of 
which 0.7 million comprised patients who were co-infected 
with human immunodeficiency virus (HIV). Of 1.7 million 
TB-related deaths, 0.2 million were patients with HIV 
infection[1].
  A report of the National Center for the Prevention and 
Control of HIV/acquired immunodeficiency syndrome (AIDS) 
(CENSIDA, its acronym in Spanish) in Mexico noted that 
Mexico occupies 42nd place worldwide in number of cases 
and the 16th place in Latin America. To March 31, 2009 in 
the National Registry of AIDS Cases in Mexico, 130 969 cases 
had been accounted for in accumulated manner, of whom 
82% were males and 18%, females. In addition, it has been 
estimated that in Mexico there are ca. 200 000 persons with 
HIV/AIDS[2].
  Prevention of active TB (ATB) by means of latent 
tuberculosis infection (LTBI) treatment is one of the greatest 
strategic elements to eliminate TB, particularly in the US[3]. 
It has been calculated that ca. 5%-10% with the latent 
form of tuberculosos (LTBI) will progress to active disease 
during their lifetime, and subjects co-infected with HIV 
and TB exhibit an active disease-progression degree of 3.5% 
to16.2%[4]. This will increase up to 20% or more in persons 
who are tuberculin skin test (TST)-positive[5]. However, this 
test has limitations, yielding false-positive results when 
the individual has the antecedent of the Bacillus Calmette-
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Guerin vaccination in the last 15 years and exposure to 
environmental non-tuberculous mycobacteria (NTM)[6]. 
Likewise, the low sensitivity and specificity of this test 
have been reported in patients with HIV and pulmonary TB 
with anergy up to 24.6% and associated with low Cluster of 
differentiation (CD4) count[7].
  In recent years, a new generation of diagnostic tests 
for LTBI, the T cell-based IGRAs, have been developed: 
QuantiFERON襅-Cell mediated immune (QFT-CMI) 
(Cellestis, Carnegie, Australia)[8,9]. IGRAs measure the 
amount of IFN毭 released from sensitized T-cells after 
exposure to Mycobacterium tuberculosis antigens[10]. Studies 
examining the diagnostic sensitivity of IGRAs in HIV-
seropostitive patients suggest that the assay possesses higher 
sensitivity than the TST[11].
  The purpose of our study was to assess the usefulness of 
IGRAs, specifically QTF-CMI, among HIV-infected persons 
and to determine the degree of concordance between two 
diagnostic tests for LTBI (TST and QFT-CMI). 
2. Materials and methods
2.1. Study population and setting
  A cross-sectional study was carried out at the Infectology 
Hospital and at the Immunology and Infectology Medical 
Research Unit of the National Medical Centre La Raza of 
the Mexican Social Security Institute in Mexico City. The 
study included patients with HIV-AIDS and the suspicion or 
with LTBI who were >18 years of age and without treatment 
for TB. Information was gathered from March through 
December, 2006. Of the 34 patients selected for the study, 25 
accepted to participate in the study after signing informed 
consent. The study protocol was reviewed and approved by 
the Institutional Ethics Committee. Patients were selected 
during their consultancy appointments, the latter including 
clinical evaluation, viral load control, treatment compliance, 
and appraisal of potential side effects. Clinical information 
comprising age, gender, year of diagnosis of HIV, the 
diagnosis that defined AIDS, and other risk factors for TB 
such as exposure to an index case with positive sputum, 
were gathered by means of review of the patients’ clinical 
files. We excluded patients with type 2 diabetes, with 
previous severe reaction to TST or with active opportunistic 
infections.
Case study definitions were the following:
  Patients with LTBI: the patient with HIV/AIDS infected with 
TB without radiological and clinical manifestations and with 
positive TST, who could potentially develop ATB within an 
undetermined time.
 Patient with the suspicion of LTBI: patient with HIV/AIDS 
with radiological or clinical manifestations and with negative 
TST who have the antecedent of exposure to TB or who reside 
in a country with high TB endemicity.
2.2. T-cell interferon-gamma release assay
  The QFT test  was carried out  according to the 
manufacturer’s instructions. Briefly, 1 mL of the heparinized 
whole blood of each subject was placed in three wells of a 
24-well culture plate. We added mitogen, purfied protein 
derivative (PPD) antigen skin test, and negative control to 
appropriate wells. The plates were incubated for 16 -24 h at 
37 曟 in a humid atmosphere; later, the plasma supernatant 
was removed and frozen until use. The amount of IFN
毭 produced was determined employing enzyme-linked 
immunosorbent assay, and liberation of IFN毭 in the saline 
control tube was subtracted from that of Phytohemagglutin 
(PHA)- and TB (PPD)-stimulated tubes. Samples with 曒
0.35 IU/mL of IFN毭 following stimulation with TB-specific 
antigen (PPD) were considered positive, while samples with 
<0.35 IU/mL were considered negative. 
  Alter blood was drawn for the IGRA, a TST was conducted 
utilizing the Mantoux method[12]; 0.1 mL [5 tuberculin units 
of PPD (Tubersol; Sanofi Pasteur, Inc., Swiftwater, PA, USA)] 
was administered intradermally (i.d.). TST was measured at 
between 48 and 72 h by a trained reader. Induration of 曒5 
mm was considered positive[9].
 On the other hand, there are four classical criteria for the 
study of contacts of tuberculosis patients (COMBE test): 
epidemiological, clinical, tuberculin and radiological. If the 
analysis of these criteria suggests the possibility of a case of 
tuberculosis, can do a better study of diagnostic aids such 




 Agreement was assessed using k, where k 斁0.75 represents 
excellent agreement, k values ranging from 0.4-0.75 
represent fair-to-good agreement, and k <0.4 represents 
poor agreement, beyond chance[13]. Median values were 
compared utilizing the Mann-Whitney U test. We also 
employed central-trend, bivariate-analysis, and Pearson-
correlation measurements.
3. Results
  A total of 25 HIV-infected persons were enrolled in the 
study. Baseline characteristics of the patient population are 
displayed in Table 1. Twenty three patients were receiving 
highly effective antiretroviral therapy (HAART), and the most 
frequent combinations were the following: six patients (2 
ITRN + 1 ITRnN); three patients (2 IRTnN + 1 IP); three patients 
(2 ITRN+ 1 IPr), and one patient (1 ITRN + 2 IP) (data not 
shown). 
  Thirteen patients had normal chest teleradiography 
(median IFN毭 2.5 UI/mL) and 12 patients with indistinct 
radiographic patterns suggesting no TBA (Table 2). 
Overall, 20 (80%) of 25 patients had at least one positive 
diagnostic test for LTBI. Among the 25 patients who had their 
TST read, four (16%) were positive, and 19 of the 25 patients 
(76%) had a positive QFT. 
  Only three patients had positive test results for both 
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diagnostic tests (TST and QFT). There was no agreement 
between TST and QFT [k = 0.004, 95% CI -(0.2219, 0.2210)].  
  No association was found between concentrations of IFN
毭 and stage of disease in patients with HIV/AIDS utilizing 
the Mann-Whitney U test. There was also no correlation to 
analyze the lymphocyte subsets CD4, CD8, CD3 and viral 
load in IFN毭, using the Pearson correlation test.
Table 1
Baseline characteristics of  population (n = 25). 
Patient characteristics Numbers 
(percentages)
Age in years, median (range) 34 (19 - 65)
Gender Masculine 24 (96%)
Feminine 1 (4%)
HIV history C D 4  c e l l  c o u n t s , 
median (range)
364 (7 -842 cells/毺L)
Viral load, median (ra
nge)                                                                                   
12暳10
3 (50 -106 copies/
mL)
Duration in years of 
HIV diagnosis, median 
(range)
6 (1-18)
Patients on HAART 23 (92%)






Teleradiography-ray analysis and correlation with positivity for 
COMBE, TST and mean values of IFN毭(n = 25).








infiltrate suggesting no 
ATB
10 1(10) 3(30) 4.3
Calcified pulmonary 
nodule
  2 2(100) 0(0) 8.0
Pulmonary overdistencion   1 0(0) 0(0) 5.0
Normal 12 2(17) 1(8) 1.3
4. Discussion
  The most striking finding in our study comprised the very 
poor agreement found between the two different tests, with 
a k value of -0.004. Other studies also have also found poor 
concordance between TST and QFT[14]. Overall prevalence 
of a positive test with TST was 16%, and with QFT, was 76%. 
However, only three individuals tested positive for both 
tests.
  In this study, we found a high percentage of patients with 
HIV/AIDS and positive IFN毭(76%), higher than percentages 
reported in other related studies, in which prevalences 
was 4.6% in European countries, 13% in countries with 
high endemicity, 16% when there was an epidemiological 
antecedent of exposure, and 60% to 70% in contacts with 
patients with active TB and in those who reside in high-
endemicity zones[15]. 
  Prior publications report that subpopulations low in CD4 
(<200 cells) are associated with anergy on being tested for 
TST (in vivo and in vitro)[7,15,16]. There is little information in 
the literature on IFN毭 on individuals with HIV/AIDS; in our 
study,  five patients  had low CD4 values; of these, four (80%) 
had IFN毭values that were >5 IU/mL, and of these, three had 
IFN毭values >10 IU/mL. Thus, our values are different from 
those published in the literature[8,17].
  In this study, we analyzed variables such as history of 
exposure to TB. We found that in patients who were positive 
COMBE (TB contact), median IFN毭 value was 3.1 IU/mL, in 
comparison with patients with negative COMBE, in whom 
this was 3.8 IU/mL, although without statistical significance, 
which can be related with the number of patients studied.
  Likewise, we analyzed variables such as age, gender, CD4 
count, and RNA-HIV viral load, and found no correlation 
with IFN毭 levels, this similar to that reported in the 
literature[8,15,18].
  In patients with HIV/AIDS, radiological manifestations are 
modified by the degree of immune compromise; patterns 
can be diverse, such as superior-lobule pleural cavities, 
infiltrate, nodules, and pleural leakage. Some series report 
a lesser incidence of cavitary disease, a greater frequency 
of mean pulmonary infiltrate, and less in comparison 
with clinical reactivation pictures in immunocompetent 
population[19]. In this study, the main radiological finding 
was bilateral diffuse interstitial infiltrate.  
  This study does not resolve the question of whether QFT 
testing should be performed simultaneously with, or instead 
of, TST testing in HIV-infected patients. On the one hand, 
the significant risk of LTBI reactivation in HIV-infected 
subjects presents a case for simultaneous screening with 
both TST and QFT to minimize false-negative tests and 
missed opportunities for LTBI therapy[20]. Until further data 
are available on the implication of discordant TST and QFT 
results, a strategy of simultaneous TST and QFT testing, when 
feasible, would maximize potential LTBI diagnoses in HIV-
infected subjects.
  On the other hand, simultaneous QFT and TST may be 
unrealistic in many settings. TST limitations, which include 
poor performance in HIV-infected populations[21,22] and 
personnel requirements for appropriate placement and 
interpretation, render a one-visit blood test attractive for 
LTBI diagnosis.
  In this study, PPD-stimulated IFN毭levels exhibited a 
median of 3.8 IU/mL (10 times the positive cut-off value). 
Patients with positive TST and Combe presented the highest 
levels of IFN毭 Given that tests with IFN毭 are more 
sensitive than TST, the cost-benefit of diagnosis of LTBI 
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should be appraised in patients with HIV/AIDS, and QFT 
implementation as sole test in this population, application of 
a timely prophylactic treatment, and performance of follow-
up studies with newIFN毭 determinations after 2 years of 
prophylactic-treatment application should be proposed. 
This study is limited by its small number of subjects and 
its cross-sectional design, which preclude prospective 
evaluation of TB incidence. 
  In conclusion, our findings indicate poor agreement 
between the TST and IGRA assays. Additional studies, 
preferably with a longitudinal design, in HIV-infected 
individuals are required to determine the true role that IGRA 
will play in the diagnosis of LTBI in these patients.
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